Breaking News

Aptar Pharma’s Electronic Lockout Device Approved by EMA

Reinforces a long-standing partnership between Aptar Pharma and Takeda

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Aptar Pharma has received approval by the European Medicines Agency (EMA) of the first integrated electronic nasal lockout device (e-Lockout) following a multi-year development with Takeda Pharmaceuticals International AG. Aptar Pharma agreed to supply Takeda with its e-Lockout device for a multidose nasal spray version of Instanyl. The EMA has granted marketing authorization for this multidose nasal spray treatment under the name Instanyl DoseGuard. This represents a major milestone for Apta...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters